Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ilex/Lilly Development Agreement Grows Out Of CRO Contract For Cancer Drug

Executive Summary

Ilex Oncology will initiate Phase II trials for Lilly's diarysulfonylurea anticancer compound LY295501 in mid-1999. The drug developer and contract research service provider is currently writing protocols for four Phase II studies in lung, ovarian and kidney cancer and melanoma.

You may also be interested in...



Ilex Has 16 Products For Internal Development After Convergence Acquisition

Ilex Oncology is adding seven compounds to its pipeline with the acquisition of Boston-based Convergence Pharmaceuticals.

Ilex Has 16 Products For Internal Development After Convergence Acquisition

Ilex Oncology is adding seven compounds to its pipeline with the acquisition of Boston-based Convergence Pharmaceuticals.

Ilex Strengthens European CRO Presence Via U.K. Acquisition

Ilex' buyout of the U.K. component of its alliance with Munich-based PFK-Ilex will strengthen its presence in the European CRO market.

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel